Author(s):
Kalyani Sanjaykumar Patil, Javesh K. Patil, J. K. Patil
Email(s):
kalyanipatil1820@gmail.com
DOI:
10.52711/2231-5675.2026.00050 
Address:
Kalyani Sanjaykumar Patil1*, Javesh K. Patil2, J. K. Patil2
1P.S.G.V.P Mandal's College of Pharmacy, Shahada, Dist. Nandurbar, Maharashtra, India.
2Assistant Professor, Department of Pharmaceutical Quality Assurance, PSGVP Mandal’s College of Pharmacy, Shahada, Maharashtra, India.
2P.S.G.V.P Mandal's College of Pharmacy, Shahada Dist. Nandurbar, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2026
ABSTRACT:
The pharmaceutical various combinations of Dapagliflozin (DAPA) and Teneligliptin hydrobromide hydrate (TEN) drugs is used in the treatment of type 2 diabetes mellitus. Dapagliflozin and Teneligliptin are the SGLT-2 and DPP-4 classes inhibitors for the treatment of type II diabetes mellitus. SGLT-2 and DPP-4 is the class of anti-diabetic medicine also called gliflozin and gliptin respectively. The aim of this review is to focus on update of determination of Dapagliflozin and Teneligliptin in bulk and in pharmaceutical dosage forms using different analytical methods. A simple, novel, precise, rapid, accurate, specific high-performance liquid chromatography (HPLC) method for estimation of Teneligliptin hydrobromide hydrate and Dapagliflozin propanediol monohydrate API in marketed formulation was developed and validated. Two popular antidiabetic medications from the SGLT-2 inhibitor and DPP-4 inhibitor groups are dapagliflozin and teneligliptin hydrobromide hydrate. Reliable analytical techniques are required for routine quality control, stability testing, and pharmacokinetic evaluation because to their growing use in fixed-dose combination therapy. The analytical methods for estimating dapagliflozin and teneligliptin in bulk medications, pharmaceutical dosage forms, and biological matrices are compiled in this review. UV-visible spectrophotometry, derivative spectroscopy, RP-HPLC, HPTLC, UPLC, and LC-MS/MS are some of the techniques used. Because chromatographic procedures have greater sensitivity, specificity, and stability-indicating capacity, they are chosen.
Cite this article:
Kalyani Sanjaykumar Patil, Javesh K. Patil, J. K. Patil. A Thorough Analysis of Analytical Techniques for Determining Dapagliflozin and Teneligliptin Hydrobromide Hydrate in Single and Combination Dosage Forms. Asian Journal of Pharmaceutical Analysis. 2026; 16(4):325-1. doi: 10.52711/2231-5675.2026.00050
Cite(Electronic):
Kalyani Sanjaykumar Patil, Javesh K. Patil, J. K. Patil. A Thorough Analysis of Analytical Techniques for Determining Dapagliflozin and Teneligliptin Hydrobromide Hydrate in Single and Combination Dosage Forms. Asian Journal of Pharmaceutical Analysis. 2026; 16(4):325-1. doi: 10.52711/2231-5675.2026.00050 Available on: https://www.ajpaonline.com/AbstractView.aspx?PID=2026-16-4-12
REFERENCES:
1. Tripathi KD. Essentials of medical Pharmacology. JP Medical Ltd; 2013 Sep 30.
2. Patel H, Chakraborty GS, Patel P. An Updated Review on Analytical Methods for Estimation of Teneligliptin and Dapagliflozin. International Journal of Biomedical and Pharmaceutical Analysis Sciences. 2024; 13(3): 1369–1386. DOI: 10.31032/IJBPAS/2024/13.3.7880.
3. Kashyap T, Honey K, Priyanka V, et al. Novel RP-HPLC method for simultaneous determination of dapagliflozin and teneligliptin in tablet formulation and identification of degradation products by LC-MS/MS. Futur J Pharm Sci. 2024; 10: 154. DOI: 10.1186/s43094-024-00734-x
4. PubChem. Dapagliflozin. PubChem Compound Database. National Center for Biotechnology Information; CID=9887712. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/9887712 (Accessed on: 02 April 2026).
5. List, J. F., and Whaley, J. M. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney International. 2011; 79(S120): S20–S27. https://doi.org/10.1038/ki.2010.512
6. DeFronzo RA, et al. Mechanism of action and pharmacokinetics of SGLT2 inhibitors in type 2 diabetes mellitus. Diabetes Care. 2015; 38(3): 428–439. DOI: 10.2337/dc14-1796.
7. Scheen AJ. Pharmacodynamics, efficacy and safety of SGLT2 inhibitors in type 2 diabetes mellitus. Nature Reviews Endocrinology. 2015;11(1):11–26. DOI:10.1038/nrendo.2014.190.
8. PubChem – Teneligliptin Hydrobromide Hydrate (CID: search PubChem for up-to-date entry) https://pubchem.ncbi.nlm.nih.gov(Accessed 2026)
9. https://pubchem.ncbi.nlm.nih.gov/compound/53297474 (Accessed April 2026)
10. Scott LJ. Teneligliptin: a review in type 2 diabetes. Clinical Drug Investigation. 2015 Nov; 35(11):765–772. doi:10.1007/s40261-015-0348-9.
11. Kishimoto M, Yamaguchi Y, Uno T. Teneligliptin: A novel DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Journal of Diabetes Investigation. 2012; 3(1): 1–7. DOI: 10.1111/j.2040-1124.2012. 00205.x.
12. Teneligliptin (DB06234) – Drug Profile. https://go.drugbank.com/drugs/DB06234 (Accessed April 2026).
13. PubChem. Teneligliptin Hydrobromide Hydrate; CID 53297474. National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/53297474 (Accessed April 2026).
14. Kishimoto M, Yamaguchi Y, Uno T. Teneligliptin: A novel DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Journal of Diabetes Investigation. 2012; 3(1): 1–7. DOI: 10.1111/j.2040-1124.2012.00205. x.
15. Deacon CF. Pharmacology, physiology, and mechanisms of action of DPP-4 inhibitors. Diabetes, Obesity and Metabolism. 2011; 13(Suppl 1): 1–8. DOI: 10.1111/j.1463-1326.2011.01436. x.
16. Teneligliptin (DB06234). Drug Bank Online. Available from: https://go.drugbank.com/drugs/DB06234 (Accessed April 2026).
17. Kashyap, T., Honey, K., Priyanka, V., and Mihir, J. (2024). Novel RP-HPLC method for simultaneous determination of dapagliflozin and teneligliptin in tablet formulation and identification of degradation products by LC-MS/MS. Future Journal of PharmaceuticalSciences,10, Article154.https://doi.org/10.1186/s43094-024-00734-x
18. Drashti A. Mandale, Chainesh Shah and Rakesh Jatt. Simultaneous Estimation of Rosuvastatin and Teneligliptin in Synthetic Mixture by UV Spectrometer. World Journal of Pharmacy and Pharmaceutical Sciences. 2022; 11(7): 84-93.
19. Patel A, Jadeja P, Mashru R. Analytical Method Development and Validation for Simultaneous Estimation of Dapagliflozin and Teneligliptin Hydrobromide Hydrate from Synthetic Mixture by Three Different UV Spectrophotometric Methods. World Journal of Pharmaceutical Research. 2022; 11(7): 70-83.
20. Vyas A, Godhaniya J, Patel A, Patel A, Patel N, Shah S, Sheth Development and Validation of UV-Spectroscopic First Order Derivative Method for Simultaneous Estimation of Rosuvastatin Calcium and Teneligliptin Hydrobromide Hydrate in Synthetic Mixture. Chemical Methodologies. 2021; 5(4): 17-23.
21. Maruthi R, Chandan RS, Barath M, Datta GN, D’silva M, Kumari KM, Ahmad F, Geetha R. Analytical Method development and Validation of teneligliptin by UV Spectroscopy. Research Journal of Pharmacy and Technology. 2021; 14(1): 75-80.
22. Ameeduzzafar, El-Bagory, I., Alruwaili, N. K., Imam, S. S. Alomar, F. A., Elkomy, M. H., and Elmowafy, M. Quality by design (QbD) based development and Validation of bioanalytical RP-HPLC method for dapagliflozin: Forced degradation and preclinical Pharmacokinetic study. Journal of Liquid Chromatography and Related Technologies. 2020; 43(1-2): 53-65.
23. El-Shoubashy, O. H. E., Beltagy, Y. A. E. M., Issa, A. E., and El-Kafrawy, D. S. Comparative study of HPLC-DAD and HPTLC for the Simultaneous determination of a New multitarget antidiabetic Ternary mixture in combined Tablets. JPC–Journal of Planar Chromatography–Modern TLC. 2020; 33: 59-70.
24. Attimarad, M., Venugopala, K. N., Nair, A. B., Sreeharsha, N., and Deb, P. K. Experimental design approach for quantitative expressions of Simultaneous quantification of two Binary formulations containing Remogliflozin and gliptins by RP-HPLC. Separations. 2022; 9(2): 21-23.
25. Vashi Dhara and Gamit Dharmistha. Development and validation of RP-HPLC method for stimultaneus Estimation of Remogliflozin Etabonate and Teneligliptin in Pharmaceutical dosage form. World Journal of Pharmacy and Pharmaceutical Sciences. 2022;11(8): 4-16.
26. Bhoomi Dineshkumar Patel, Nidhi J. Dharsandiya, Ankit Chaudhary. Development and Validation of RP-HPLC Method for Estimation of Teneligliptin and its Impurity in Tablet: International Journal of Pharmaceutical Sciences Review and Research. 2021; 69(2): 127-133.
27. Gunman, S., Choppari, T., Lakshmi, N. C., Cherla, P. M., and Siddiqui, S. I. Development and Validation of Teneligliptin Stereoisomers by HPLC Using Cellulose Based Immobilized Polysaccharide Chiral Stationary Phase. Current Pharmaceutical Analysis. 2021; 17(10): 1317-1322.
28. Dhale C R. Rao J R. Stability Indicating HPLC Method Development and Validation for The Simultaneous Estimation of Metformin Hydrochloride and Dapagliflozin in api and Pharmaceutical Dosage Form. Int. Res. J. Pharm. 2021; 12(8): 1-10.
29. Nachiket S. Dighe, Priyanka R. Varade, Ganesh S. Shinde, Priya S. Rao. Quantitative Estimation and Validation of Dapagliflozin and Metformin Hydrochloride in Pharmaceutical Dosage form by RP-HPLC. Asian J. Research Chem. 2019; 12(3): 136-142.
30. Saiyed Javedmiya Mukhtiyarmiya and Sibaji Sarkar. Stability Indicating Analytical Method Development and Validation for Simultaneous Estimation of Teneligliptin Hemihydrate Hydrobromide and Rosuvastatin Calcium in Synthetic Mixture. World Journal of Pharmacy and Pharmaceutical Sciences, 2022; 11(1): 16-52.
31. Murugesan, A. R. U. L. S. E. L. V. A. N., and Annapurna, M. Simple Quantified and Validated Stability Indicating Stress Degradation Studies of Oral Anti-Diabetic Agent Dapagliflozin by RP-HPLC Method. Int J App Pharm. 2022; 14(1): 231-7.
32. Patel, A., Omray, D. L., and Soni, P. Method development for Simultaneous estimation of Dapagliflozin and saxagliptin in Fixed-dose combination and Validation on UV spectroscopy. J Pharm, 2020; 9(3): 2536-43.